New Analysis Reinforces Cost-Effectiveness of the Oncotype DX Breast Recurrence Score® Test in Node-Positive Early-Stage Breast Cancer

Exact Sciences Strengthens Evidence Supporting Cologuard® and Oncotype DX® Tests and Deep Oncology Pipeline with Multiple Data Presentations at ASCO 2021

Exact Sciences Applauds Final Task Force Recommendation That Lowers Starting Age for Colorectal Cancer Screening to 45

New NCCN Breast Cancer Guidelines Recognize Oncotype DX Breast Recurrence Score® Test

JAMIE FOXX, STAND UP TO CANCER AND EXACT SCIENCES LAUNCH PSA TO INCREASE AWARENESS OF COLORECTAL CANCER

The Truth About Cancer: Debunking Five Myths about the Big C

$10 MILLION GRANT FROM EXACT SCIENCES TO SUPPORT STAND UP TO CANCER INITIATIVE TO IMPROVE COLORECTAL CANCER SCREENING AND PREVENTION

New Data at SABCS 2020 Highlight the Role of the Oncotype DX Breast Recurrence Score® Test in Shaping Clinical Practice

RxPONDER Study Results Demonstrate that the Oncotype DX® Test Can Now Spare Chemotherapy Use in the Majority of Women with Node-positive Early-stage Breast Cancer

Exact Sciences Mourns the Death of Dr. David Ahlquist, a Pioneer in Early Cancer Detection

Exact Sciences Commends Task Force for Draft Updated Guidelines that include Colorectal Cancer Screening Beginning at Age 45

Exact Sciences Introduces the Oncotype MAP™ Pan-Cancer Tissue Test to Help Guide Treatment for Patients with Advanced Cancer